TECX Tectonic Therapeutic Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: TECX

Price (delayed)

$17.67

Market cap

$66.11M

P/E Ratio

2.1

Dividend/share

N/A

EPS

$8.4

Enterprise value

-$24.43M

clinical stage company focused on delivering step-change cell & gene therapies targeting cancer and rare disease.

Highlights
The EPS has surged by 159% since the previous quarter and by 130% year-on-year
TECX's net income has surged by 149% since the previous quarter and by 130% year-on-year
Tectonic Therapeutic's equity has soared by 68% YoY but it has decreased by 6% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://avrobio.com
Peers: OMGA ONCT

Key stats

What are the main financial stats of TECX
Market
Shares outstanding
3.74M
Market cap
$66.11M
Enterprise value
-$24.43M
Valuations
Price to earnings (P/E)
2.1
Price to book (P/B)
0.74
Price to sales (P/S)
N/A
EV/EBIT
-0.86
EV/EBITDA
-0.8
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
$28.51M
EBITDA
$30.44M
Free cash flow
-$49.13M
Per share
EPS
$8.4
Free cash flow per share
-$13.16
Book value per share
$23.76
Revenue per share
$0
TBVPS
$24.74
Balance sheet
Total assets
$92.35M
Total liabilities
$3.51M
Debt
$224,000
Equity
$88.84M
Working capital
$88.33M
Liquidity
Debt to equity
0
Current ratio
26.17
Quick ratio
25.87
Net debt/EBITDA
-2.97
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
27.7%
Return on equity
29.7%
Return on invested capital
N/A
Return on capital employed
32.1%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TECX stock price

How has the Tectonic Therapeutic stock price performed over time
Intraday
3.94%
1 week
7.09%
1 month
10.92%
1 year
-2.48%
YTD
8.27%
QTD
7.29%

Financial performance

How have Tectonic Therapeutic's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
$27.47M
Net income
$30.31M
Gross margin
N/A
Net margin
N/A
TECX's operating income has surged by 170% since the previous quarter and by 127% year-on-year
TECX's net income has surged by 149% since the previous quarter and by 130% year-on-year

Growth

What is Tectonic Therapeutic's growth rate over time

Valuation

What is Tectonic Therapeutic stock price valuation
P/E
2.1
P/B
0.74
P/S
N/A
EV/EBIT
-0.86
EV/EBITDA
-0.8
EV/Sales
N/A
The EPS has surged by 159% since the previous quarter and by 130% year-on-year
Tectonic Therapeutic's equity has soared by 68% YoY but it has decreased by 6% from the previous quarter
TECX's price to book (P/B) is 45% less than its 5-year quarterly average of 1.3 but 20% more than its last 4 quarters average of 0.6

Efficiency

How efficient is Tectonic Therapeutic business performance
The return on assets has surged by 145% since the previous quarter and by 132% year-on-year
Tectonic Therapeutic's ROE has soared by 128% from the previous quarter and by 125% YoY

Dividends

What is TECX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TECX.

Financial health

How did Tectonic Therapeutic financials performed over time
The total liabilities has shrunk by 88% YoY and by 45% QoQ
Tectonic Therapeutic's quick ratio has soared by 67% from the previous quarter
TECX's debt is 100% smaller than its equity
The debt to equity has shrunk by 100% QoQ and by 100% YoY
TECX's debt has dropped by 99% year-on-year and by 74% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.